Publications

Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.

* denotes publications from the CTD2 initiative that are results of intra-Network collaborations

 

CTD²
March 01, 2020
Nature Biotechnology

CTD2 scientists at UCSF used CRISPR interference approach to study gene-specific expression–phenotype relationships and expression level-dependent cell responses at single-cell resolution. This technique could be used in drug development, functional genomics, and identification of suppressor.

CTD²
February 21, 2020
Nat Commun.

Scientists performed WGS, RNA and T-cell receptor sequencing, immunohistochemistry and reverse phase protein array profiling on pediatric and adult samples. Study indicated that genomic complexity causes immunosuppressive phenotype and provides opportunities for developing novel treatments.

CTD²
February 20, 2020
Neuro-Oncology

Risk stratification of medulloblastoma subtype could minimize the burden of cerebellar mutism syndrome burden on pediatric patients with posterior fossa tumors, a type of brain tumor located in or near the bottom of the skull.

CTD²
February 14, 2020
Clinical Cancer Research

Report on challenges and opportunities associated with translating basic science discoveries in glioblastoma discussed during the neuro-oncology community meeting in April 2019.

CTD²
February 14, 2020
Clinical Cancer Research

Stanford University used single-cell genomics to characterize heterogenous cell types and states in tumor microenvironment revealing changes in transcriptional states, regulatory networks, and intercellular communication between matched gastric tumor and normal tissue from same patients.

CTD²
February 06, 2020
Blood

Human pluripotent stem cells-derived natural killer cells have improved antibody-dependent cellular cytotoxicity and could be used to treat refractory malignancies.

CTD²
February 05, 2020
Nature Communications

Scientists analyzed whole genomes of over 2500 tumors from 27 different cancer types and identify new components of cancer pathways that are altered by coding and non-coding mutations.

CTD²
February 03, 2020
Gynecologic Oncology Reports

Phase II clinical trial with single-agent Akt inhibitor, MK2206, in recurrent platinum-resistant high-grade serous ovarian cancers with molecular aletarions in PI3K/AKT pathway is not effictive.

CTD²
February 01, 2020
Nature

CTD2 scientists developed a high-throughput in vivo complementation screening platform that enabled discovery of driver mutations of PIK3CA in glioblastoma. These studies highlight that variant function is context specific.

CTD²
January 23, 2020
Molecular Cancer Therapeutics

Studies indicate that Syk kinase plays a role in the control of macrophage-mediated immune suppression and inhibition of anti-tumor immunity. SRX3207, a dual inhibitor of PI3K and Syk kinases, inhibits macrophages polarization and activates innate and adaptive antitumor immunity in vivo.

Pages

CSVXML